6533b835fe1ef96bd129eae6

RESEARCH PRODUCT

A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children.

P. HabermehlDorothee Kieninger-baumP. MuttonenHartwig MaurerPeter VinkJan PoolmanDominique BoutriauMarkus Knuf

subject

MalePediatricsmedicine.medical_specialtyMeningococcal VaccinesMeningococcal diseasePolysaccharide Vaccinemedicine.disease_causeConjugate vaccinemedicineTetanus ToxoidHumansVaccines ConjugateGeneral VeterinaryGeneral Immunology and MicrobiologyTetanusbusiness.industryImmunogenicityNeisseria meningitidisPublic Health Environmental and Occupational HealthToxoidInfantmedicine.diseaseAntibodies BacterialMeningococcal InfectionsInfectious DiseasesChild PreschoolImmunologyMolecular MedicineFemalebusinessConjugate

description

Meningococcal disease incidence is highest in young children, yet a tetravalent conjugate vaccine is currently not available for this age group. This study evaluated a single dose of four different ACWY-TT conjugate vaccine formulations in 240 toddlers (12-14 months) and 268 children (3-5 years) compared to licensed age-appropriate control vaccines. In toddlers, rSBA-MenC GMTs for the selected formulation were statistically higher than after monovalent-MenC-conjugate vaccine. In children, rSBA-GMTs against each serogroup were statistically higher than after tetravalent polysaccharide vaccine. The safety profile was comparable to licensed controls. The new ACWY-TT conjugate vaccine promises high seroprotection levels against meningococcal disease from 1 year of age.

yearjournalcountryeditionlanguage
2009-03-20Vaccine
10.1016/j.vaccine.2009.10.064https://pubmed.ncbi.nlm.nih.gov/19887137